肺癌采用细胞疗法：鼓舞人心的 TIL ACT 登上舞台中央。

IF 29.7 1区医学 Q1 ONCOLOGY

Cancer discovery Pub Date : 2024-08-02 DOI:10.1158/2159-8290.CD-24-0645

Michael T Lotze, Markus Maeurer, Sergio A Quezada, George Coukos

{"title":"肺癌采用细胞疗法：鼓舞人心的 TIL ACT 登上舞台中央。","authors":"Michael T Lotze, Markus Maeurer, Sergio A Quezada, George Coukos","doi":"10.1158/2159-8290.CD-24-0645","DOIUrl":null,"url":null,"abstract":"Schoenfeld and colleagues report, in this issue, a measurable objective response rate in 6/28 (21.4%) of patients with advanced non-small cell lung cancer treated with lifileucel, a cell therapy product based on autologous tumor-infiltrating lymphocytes (TIL). Extending solid evidence in advanced melanoma that led to FDA approval of lifileucel, this new evidence bodes well for treating patients with other common tumor histologies, justifying important efforts by a large number of academic and biotechnology companies engaged in improving the TIL process. See related article by Schoenfeld et al., p. 1389 (1).","PeriodicalId":9430,"journal":{"name":"Cancer discovery","volume":"14 8","pages":"1366-1368"},"PeriodicalIF":29.7000,"publicationDate":"2024-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Lung Cancer Adoptive Cell Therapy: Inspiring TIL ACT Comes Center Stage.\",\"authors\":\"Michael T Lotze, Markus Maeurer, Sergio A Quezada, George Coukos\",\"doi\":\"10.1158/2159-8290.CD-24-0645\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Schoenfeld and colleagues report, in this issue, a measurable objective response rate in 6/28 (21.4%) of patients with advanced non-small cell lung cancer treated with lifileucel, a cell therapy product based on autologous tumor-infiltrating lymphocytes (TIL). Extending solid evidence in advanced melanoma that led to FDA approval of lifileucel, this new evidence bodes well for treating patients with other common tumor histologies, justifying important efforts by a large number of academic and biotechnology companies engaged in improving the TIL process. See related article by Schoenfeld et al., p. 1389 (1).\",\"PeriodicalId\":9430,\"journal\":{\"name\":\"Cancer discovery\",\"volume\":\"14 8\",\"pages\":\"1366-1368\"},\"PeriodicalIF\":29.7000,\"publicationDate\":\"2024-08-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer discovery\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1158/2159-8290.CD-24-0645\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer discovery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1158/2159-8290.CD-24-0645","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

Schoenfeld及其同事在本期杂志上报告说，6/28（21.4%）名晚期非小细胞肺癌患者接受了基于自体肿瘤浸润淋巴细胞（TIL）的细胞疗法产品lifileucel的治疗，获得了可测量的客观反应率。在晚期黑色素瘤的确凿证据促使美国食品及药物管理局批准了利匹灵的基础上，这一新证据预示着治疗其他常见肿瘤组织学的患者也会有很好的效果，这也证明了大量学术界和生物技术公司在改进TIL过程中所做的重要努力是正确的。参见 Schoenfeld 等人的相关文章，第 1389 页 (1)。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Lung Cancer Adoptive Cell Therapy: Inspiring TIL ACT Comes Center Stage.

Schoenfeld and colleagues report, in this issue, a measurable objective response rate in 6/28 (21.4%) of patients with advanced non-small cell lung cancer treated with lifileucel, a cell therapy product based on autologous tumor-infiltrating lymphocytes (TIL). Extending solid evidence in advanced melanoma that led to FDA approval of lifileucel, this new evidence bodes well for treating patients with other common tumor histologies, justifying important efforts by a large number of academic and biotechnology companies engaged in improving the TIL process. See related article by Schoenfeld et al., p. 1389 (1).

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Cancer discovery ONCOLOGY-

CiteScore

22.90

自引率

1.40%

发文量

838

审稿时长

6-12 weeks

期刊介绍： Cancer Discovery publishes high-impact, peer-reviewed articles detailing significant advances in both research and clinical trials. Serving as a premier cancer information resource, the journal also features Review Articles, Perspectives, Commentaries, News stories, and Research Watch summaries to keep readers abreast of the latest findings in the field. Covering a wide range of topics, from laboratory research to clinical trials and epidemiologic studies, Cancer Discovery spans the entire spectrum of cancer research and medicine.